RxDoctor Payments Data

Norman Foster

Neurology · Salt Lake City, UTNPI 1033209630

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,175 of the $5,190 with a category attached, or 99.7%. Biogen accounts for 60.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $3,150 and has fallen 99.5% since, to $15 in 2022.

$5,190in general payments, 2019–2025

Across 3 payments — averaging $1730.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3K
  • Eisai Inc.$2K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$15
$2,673,255in research payments, 2019–2025

Across 79 payments — averaging $33,839 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$1.9M
  • AbbVie$718K
  • Eli Lilly$45K
  • Eisai Inc.$44K

What the payments were for

  • Consulting fees$5,175100%
  • Food & beverage$150%

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,190 in reported general payments places this provider in the 65th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah

Other neurology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →